Table 1.
Baseline characteristics.
| Baseline characteristic | Combined cohorts(n = 221) | TRIUMPH sub-group(n = 148) | BEAT iTNP sub-group(n = 73) |
|---|---|---|---|
| Age, years (mean (range)) | 56 (18–78) | 54 (18–75) | 58 (22–78) |
| Males > 60 years, n (%) | 17 (8) | 8 (5) | 9 (12) |
| Female, % | 79% | 83% | 70% |
| Etiology, n (%) | |||
| Idiopathic or familial PAH | 123 (56) | 78 (53) | 45 (62) |
| Collagen vascular disease | 72 (33) | 51 (35) | 21 (29) |
| Other | 26 (12) | 19 (13) | 7 (10) |
| Background PAH therapy, % | |||
| None | 6% | 0% | 18% |
| ERA | 49% | 68% | 11% |
| PDE5-I | 29% | 32% | 22% |
| ERA + PDE5-I | 15% | 0% | 47% |
| sGC stimulator + ERA | 1% | 0% | 3% |
| 6MWD (m), median (IQR) | 342 (285, 403) | 352 (298, 404) | 326 (244, 386) |
| ≥440, n (%) | 22 (10) | 10 (7) | 12 (16) |
| 320 to < 440, n (%) | 119 (54) | 91 (62) | 28 (38) |
| 165 to <320, n (%) | 72 (33) | 47 (32) | 25 (34) |
| ≤165, n (%) | 8 (4) | 0 (0) | 8 (11) |
| NT-proBNP (pg/mL), median (IQR) | 611 (214–1400) | 636 (215–1483) | 561 (211–1210) |
| <300, n (%) | 73 (33) | 48 (32) | 25 (34) |
| 300 to < 1100, n (%) | 81 (37) | 54 (37) | 27 (37) |
| ≥1100, n (%) | 67 (30) | 46 (31) | 21 (29) |
| NYHA/WHO FC | |||
| Class III, n (%) | 211 (96) | 144 (97) | 67 (92) |
| Class IV, n (%) | 10 (5) | 4 (3) | 6 (8) |
| Heart rate | |||
| >96 beats per minute, n (%) | 20 (9) | 15 (10) | 5 (7) |
| ≤96 beats per minute, n (%) | 201 (91) | 133 (90) | 68 (93) |
| Systolic blood pressure, n (%) | |||
| <110 mmHg | 77 (35) | 58 (39) | 19 (26) |
| ≥110 mmHg | 144 (65) | 90 (61) | 54 (74) |
| Renal insufficiency, n (%) | 44 (20) | 24 (16) | 20 (27) |
| REVEAL 2.0 | |||
| RRS, mean ± SD | 7.41 ± 2.4 | 7.36 ± 2.2 | 7.51 ± 2.4 |
| Risk stratum, % (low/intermediate/high) | 36/30/34 | 35/31/35 | 38/29/33 |
| French noninvasiveNumber of low-risk criteria, % (0/1/2/3) | 64/32/5/0 | 66/32/2/0 | 60/30/10/0 |
6MWD: six-minute walk distance; ERA: endothelin receptor antagonist; PAH: pulmonary arterial hypertension; NT-pro BNP: N-terminal pro-brain natriuretic peptide; NYHA: New York Heart Association; PDE5-I: phosphodiesterase type 5 inhibitor; RRS: REVEAL 2.0 risk score; SD: standard deviation; sGC: soluble guanylate cyclase; WHO FC: World Health Organization Functional Classification; REVEAL: Registry to Evaluate Early and Long-term PAH disease management; IQR: interquartile range.
Note: renal insufficiency was defined as an eGFR < 60 mL/min/1.73 m2.